DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Varlilumab
Varlilumab
Predictive QSAR Tools to Aid in Early Process Development of Monoclonal Antibodies
RT+IO Therapy in NSCLC Draft 4 Clinical Cancer Research 1
Celldex Therapeutics Presents Phase 1 Study of Varlilumab and Opdivo® at 2017 ASCO Annual Meeting
Classification Decisions Taken by the Harmonized System Committee from the 47Th to 60Th Sessions (2011
Tanibirumab (CUI C3490677) Add to Cart
Immune Checkpoint Inhibition in DLBCL Immunotherapy: “The Cure Is Inside Us”
On the Horizon: Immuno-Oncology (I-O) Combinations
The Two Tontti Tudiul Lui Hi Ha Unit
A Review of Current Biologics Targeting OX40, 4-1BB, CD27, and GITR
WO 2016/176089 Al 3 November 2016 (03.11.2016) P O P C T
INN-Nimet 1 1.4.2019 a Abacavir Abacavirum Abakaviiri Abagovomab Abagovomabum Abagovomabi Abaloparatide Abaloparatidum Abalopara
Developmental Therapeutics Immunotherapy
Outlook for Global Medicines Through 2021 Balancing Cost and Value
United States Patent (10 ) Patent No.: US 10,471,211 B2 Rusch Et Al
Stembook 2018.Pdf
A Abacavir Abacavirum Abakaviiri Abagovomab Abagovomabum
NETTER, Jr., Robert, C. Et Al.; Dann, Dorf- (21) International Application
2018 Medicines in Development for Cancer
Top View
(INN) for Biological and Biotechnological Substances
Celldex Presents Promising Data from Phase 1/2 Study of Varlilumab and Opdivo® at 2018 ASCO Annual Meeting
15-ICML Scientificprogram June 1
WO 2017/011544 Al 19 January 2017 (19.01.2017) P O PCT
International Nonproprietary Names (INN) for Biological and Biotechnological Substances
2019 Universal Registration Document Including the Annual Financial Report
Immune Profiling and Immunotherapeutic Targets in Pancreatic Cancer
International Nonproprietary Names for Pharmaceutical Substances (INN)
Adult Cancers
Safety and Activity of Varlilumab, a Novel and First-In-Class Agonist Anti-CD27 Antibody, for Hematologic Malignancies
Identifying Major Immune Subsets of GI Tumors for Clinical
THERAPY CODES 4-Factor Concentrate F014 5A2A F017
(12) Patent Application Publication (10) Pub. No.: US 2017/0173267 A1 Ashmead Et Al
Theranostics Personalized Neoantigen Vaccination With
Update of Early Phase Clinical Trials in Cancer Immunotherapy
Meeting the Potential of Immunotherapy: New Targets Provide Rational Combinations Jane De Lartigue, Phd
Looking for Therapeutic Antibodies in Next Generation Sequencing Repositories
CD137 As an Attractive T Cell Co-Stimulatory Target in the TNFRSF for Immuno-Oncology Drug Development